FUNDING$120M Placement
Bolt Biotherapeutics Buys Prana, Raises $120M For PRA-216
Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger and raised a concurrent $120 million private placement to advance Prana's lead bispecific antibody, PRA-216.
DEEP DIVE